Blueprint Medicines (BPMC) PT Raised to $70 at Wedbush
Wedbush analyst David Nierengarten raised his price target on Blueprint Medicines (NASDAQ: BPMC) to $70.00 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)